Stock News and Filings Feed


Add COV
to your dashboard

Covalon Technologies Announces Conference Call To Discuss Q3 Financial Results

2017-08-18 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, has scheduled a conference call to be held Tuesday August 22, 2017 at 9:00 a.m. EDT, to discuss the third quarter ended June 30, 2017, financial results. The Company intends to release its Q3 financial results on Monday August 21, 2017.

Covalon Technologies Ltd. Announces First Time Attendance At The 32nd Annual Conference

2017-07-06 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be exhibiting for the first time at the 32nd Annual Oley Consumer/Clinician Conference taking place at the Hyatt Regency in Old Greenwich, CT from July 5-8, 2017.

Global Hydrophilic Coatings Market is Expected to Reach US$ 1,026.6 Mn in 2025: Transparency Market Research

2017-06-08 prnewswire
Transparency Market Research has published a new report titled "Hydrophilic Coatings (Polymers, Metals & Metal Alloys and Glass & Other Ceramics) Market for Automotive, Aerospace, Medical Devices (Cardiovascular, Urology, Neurology, General Surgery and Others) Optical and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 - 2025." According to the report, the global market for hydrophilic coatings was valued at US$ 481.

Covalon Technologies Ltd. Releases Second Quarter Financial Results

2017-05-30 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, announced today its second quarter financial results, which included revenue of $6,005,336 and net income of $473,524 or $0.02 per share for the three months ended March 31, 2017 and revenue of $11,571,005 and net income of $1,011,188 or $0.05 per share for the six months ended March 31, 2017.

Covalon Technologies Ltd. Brings Aboard Advisors to Hunt for Strategic Acquisitions

2017-05-16 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it has engaged MPA Morrison Park Advisors Inc. (“MPA”) as a financial advisor to help the Company accelerate its growth and expansion by pursuing strategic acquisitions and enhance the Company’s profile in the capital markets and investment community.

Covalon Technologies Ltd. Launches Centaur Low Particulate, Lubricious Coating For Medical Devices

2017-04-27 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced the launch of its new, Centaur™ low particulate, lubricious coating designed to improve the safety and functionality of intravascular medical devices such as catheters, guidewires and delivery sheaths where the presence of unwanted particulate can cause significant patient complications.

Research Reports Initiated on Healthcare Stocks Sirona Biochem, MedMira, Covalon Technologies, and Revive Therapeutics

2017-04-10 accesswire
LONDON, UK / ACCESSWIRE / April 10, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Sirona Biochem, MedMira, Covalon Technologies, and Revive Therapeutics.

Covalon Technologies Ltd. Announces Issuance Of Stock Options

2017-02-09 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced the issuance of an aggregate of 265,000 stock options to employees and consultants of the Company. The stock options will vest over three years and will be exercisable for a period of five years at an exercise price of $2.20 per stock option.

BRIEF-Covalon posts record first quarter financial results

2017-01-30 reuters
* Covalon Technologies Ltd qtrly revenue of $5.6 million $2.4 million Source text for Eikon: Further company coverage:

Implantable Biomaterials Market Material, Application Analysis & Trends 2016-2025: $150+ Billion Growth Opportunities/Investment Opportunities - Research and Markets

2017-01-19 prnewswire
The Global Implantable Biomaterials Market is poised to grow at a CAGR of around 7.5% over the next decade to reach approximately $165.31 billion by 2025.

Covalon Technologies Ltd. CEO Provides Update On Anticipated Fiscal 2017 Financial Growth

2017-01-03 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, announced today an update by the Company’s Chief Executive Officer on Covalon’s anticipated financial growth for fiscal 2017.

Covalon Technologies Ltd. CEO Provides Update On Anticipated Fiscal 2017 Financial Growth

2017-01-03 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, announced today an update by the Company’s Chief Executive Officer on Covalon’s anticipated financial growth for fiscal 2017.

Medical Coatings Market by Type (Hydrophilic and Hydrophobic Coating), Application (Medical Devices, Implants, Medical Equipment & Tools), and Region (Asia-Pacific, Central & Eastern Europe, North America, Western Europe and RoW) - Global Forecast t

2016-11-03 prnewswire
The global medical coatings market is projected to reach USD 15.15 billion by 2021 at CAGR of 7.04% from 2016 to 2021. This high growth is fueled by the increasing demand for medical coatings from end-use industries such as healthcare, medical devices, and others. "Metals - Fastest growing substrate type market of medical coatings" Metals are widely used in the manufacture of medical devices and implants.

Biomaterials Market is Expected to Reach $139 Billion by 2022, Globally - Allied Market Research

2016-10-04 prnewswire
A new report published by Allied Market Research, titled, "Biomaterials Market - Global Opportunity Analysis and Industry Forecast, 2014 - 2022", projects that the global biomaterials market is expected to reach $139 billion by 2022, from $62 billion in 2015, growing at a CAGR of 11.8% from 2016 to 2022. Metallic biomaterials segment is expected to contribute significantly to the global market revenue until 2022.

Covalon Technologies Ltd. Announces Exercise Of Warrants

2016-08-30 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that all of the holders of the share purchase warrants subscribed in the private placement of August 2013 that would otherwise expire on August 30, 2016, have exercised their warrants, representing a total number of 4,838,250 Common Shares of the Corporation, for a total exercise price of $749,929.

The Goldfarb Corporation Acquires Additional Shares of Covalon Technologies Ltd.

2016-08-30 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--The Goldfarb Corporation (“Goldfarb”), and Covalon Technologies Ltd. ("Covalon") (TSXV:COV), an advanced medical technologies company, announce, pursuant to National Instrument 62-103, that Goldfarb has acquired 967,650 common shares in the capital of Covalon by exercising 967,650 purchase warrants of Covalon.

Covalon Technologies Ltd. Announces Conference Call To Discuss $7.6 Million Contract To Supply ColActive Plus Dressings To Saudi Arabia

2016-08-03 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, has scheduled a conference call to be held Thursday, August 4, 2016 at 9:00 a.m. EDT, to discuss the major contract to supply its advanced ColActive Plus and ColActive Plus Ag wound care dressings to Ministry of Health facilities in Saudi Arabia at a minimum guaranteed value of $7.

Covalon Technologies Ltd. Wins $7.6 Million Twelve Month Contract To Supply ColActive Plus Advanced Wound Care Dressings To Saudi Arabia

2016-08-03 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it has won a major contract to supply its advanced ColActive Plus and ColActive Plus Ag wound care dressings to Ministry of Health facilities in Saudi Arabia at a minimum guaranteed value of $7.6 million over twelve months.

Covalon Technologies Ltd. Announces Issuance of Stock Options

2016-06-24 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, today announced the issuance of an aggregate of 200,000 stock options to employees, directors and consultants of the Company. The stock options will vest over three years and will be exercisable for a period of five years at an exercise price of $1.29 per stock option.

Covalon Technologies Ltd. Signs Distribution Agreement With Medline Industries, Inc.

2016-06-15 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it has signed a distribution agreement with Medline Industries Inc. (“Medline”), the largest privately held medical distributor in the United States, whereby Medline will be distributing Covalon-branded products, including IV Clear™, SurgiClear™, and ColActive® Plus product lines into its extensive United States customer base.

2016 Hemostats Market Pipeline Assessment and Development Covering 32 Companies

2016-06-09 prnewswire
MarketOptimizer.org adds "Hemostats - Medical Devices Pipeline Assessment, 2016" market research report that provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hemostats pipeline products.

Business Model Analysis in Antimicrobial Coatings for Medical Devices Key Players - Global Forecast to 2020

2016-06-07 prnewswire
NEW YORK, June 7, 2016 /PRNewswire/ -- Antimicrobial coatings are layered onto medical devices intended to interact with biological systems. Incessant research globally for developing highly biocompatible coatings to reduce the risk of infections is a pivotal factor stimulating the growth of the global antimicrobial coatings market for medical devices. This has led to the development of metallic (including silver, copper, and zinc) and non-metallic coatings (polymers and organic coatings, among others).